. Author manuscript; available in PMC: 2020 Dec 10.

Published in final edited form as: Pharm Res. 2014 Oct 8;32(3):1141–1157. doi: 10.1007/s11095-014-1525-x

Table VIII.

Summary of nine CYPs and UGTs expression level in pericarcinomatous tissues and tumor tissues of 15 individuals with HBV-related HCC

Isoforms	N+^a	T+^b			N/T^c			N/T^d (Avg.)	N/T^e (pooled)
Isoforms	N+^a	T+^b	<1	=1	>1	>3	>10	N/T^d (Avg.)	N/T^e (pooled)
CYP1A2	15 (100%)	8 (53%)	0	0	0	3 (20%)	12 (80%)	20.5	28.5
CYP2A6	15 (100%)	6 (40%)	2 (13%)	0	1 (7%)	3 (20%)	9 (60%)	3.4	1.7
CYP2B6	11 (73%)	1 (7%)	0	5 (33%)	0	0	10 (67%)	4.2	>4.3
CYP2C8	15 (100%)	12 (80%)	0	0	2 (13%)	3 (20%)	10 (67%)	7.5	8.5
CYP2C9	15 (100%)	15 (100%)	0	0	3 (20%)	5 (33%)	7 (47%)	6.2	8.2
CYP2C19	5 (33%)	0 (0%)	0	10 (67%)	0	0	5 (33%)	>6.8	>4.6
CYP2D6	15 (100%)	15 (100%)	0	0	3 (20%)	9 (60%)	3 (20%)	4.7	4.7
CYP2E1	15 (100%)	13 (87%)	0	1 (7%)	3 (20%)	1 (7%)	10 (67%)	3.7	5.8
CYP3A4	15 (100%)	8 (53%)	0	0	1 (7%)	3 (20%)	11 (73%)	18.2	16.7
UGT1A1	15 (100%)	15 (100%)	0	1 (7%)	3 (20%)	10 (67%)	1 (7%)	2.5	3.3
UGT1A4	15 (100%)	13 (87%)	0	1 (7%)	3 (20%)	5 (33%)	6 (40%)	4.2	4.2
UGT1A6	15 (100%)	15 (100%)	7 (47%)	5 (33%)	2 (14%)	1 (7%)	0	0.6	0.5
UGT1A9	15 (100%)	15 (100%)	3 (20%)	4 (27%)	3 (20%)	5 (33%)	0	1.8	1.9
UGT2B7	15 (100%)	15 (100%)	0	0	3 (20%)	3 (20%)	9 (60%)	6.6	6.9

Number (percentage) of positive samples prepared from pericarcinomatous tissues in which the target protein can be detected.

Number (percentage) of positive samples prepared from tumor tissues in which the target protein can be detected.

Number (percentage) of patients with certain fold change (<1,=1,>1,>3 or >10-fold) of protein amount in their tumor tissues compared with matched pericarcinomatous tissues.

Variations in average expression levels of CYPs or UGTs in 15 tumor tissues compared with pericarcinomatous tissues.

Variations in expression levels of CYPs or UGTs in tHLMs-pooled compared nHLMs-pooled.